Comparison of the Efficacy and Tolerability of Femal Versus Placebo

NACompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 10, 2019

Primary Completion Date

April 1, 2022

Study Completion Date

April 1, 2022

Conditions
Breast CancerMenopause
Interventions
OTHER

dietary supplement

"Femal, a food supplement based on pollen extracts introduced in Europe in 1999, is a non-estrogenic alternative to hormone replacement therapy in women with vasomotor symptoms.~The mechanism of action of Femal has not yet been fully clarified: Femal inhibits the absorption of serotonin in a dose-dependent manner and has strong antioxidant properties.~The lack of estrogenic effects would make this preparation of particular interest for women with a previous hormone-dependent neoplasia who undergo an early iatrogenic menopause.~Femal tablets contain a standardized formulation containing: GC Fem pollen extract 40 mg, PI82 pollen / pistil extract 120 mg, vitamin E 5 mg, amino acids 14 mg per tablet.~The dosage is 2 tablets a day orally."

Trial Locations (2)

20141

Istituto Europeo di Oncologia, Milan

00042

Policlinico Gemelli di Roma, Roma

All Listed Sponsors
lead

Azienda Ospedaliera Ordine Mauriziano di Torino

OTHER

NCT05762042 - Comparison of the Efficacy and Tolerability of Femal Versus Placebo | Biotech Hunter | Biotech Hunter